Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Galapagos NV (GLPG)

Galapagos NV (GLPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,635,245
  • Shares Outstanding, K 54,820
  • Annual Sales, $ 375,370 K
  • Annual Income, $ -34,550 K
  • 60-Month Beta 1.55
  • Price/Sales 22.92
  • Price/Cash Flow N/A
  • Price/Book 6.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.41
  • Number of Estimates 3
  • High Estimate -1.17
  • Low Estimate -1.80
  • Prior Year 0.33
  • Growth Rate Est. (year over year) -527.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
144.05 +7.63%
on 10/02/19
165.85 -6.52%
on 10/17/19
-6.04 (-3.75%)
since 09/20/19
3-Month
144.05 +7.63%
on 10/02/19
183.00 -15.28%
on 07/23/19
-32.60 (-17.37%)
since 07/22/19
52-Week
85.00 +82.40%
on 12/27/18
191.63 -19.09%
on 07/22/19
+47.14 (+43.69%)
since 10/22/18

Most Recent Stories

More News
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.

MRK : 81.30 (-3.81%)
GILD : 65.86 (+1.00%)
ALXN : 99.28 (-1.44%)
GLPG : 155.04 (-1.57%)
HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV

HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV. In...

GLPG : 155.04 (-1.57%)
Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

LLY : 109.84 (+1.79%)
NVO : 53.45 (+0.30%)
GLPG : 155.04 (-1.57%)
GILD : 65.86 (+1.00%)
GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

GLPG : 155.04 (-1.57%)
GILD : 65.86 (+1.00%)
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational,...

GLPG : 155.04 (-1.57%)
GILD : 65.86 (+1.00%)
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan

Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.

ABBV : 77.87 (+0.74%)
LLY : 109.84 (+1.79%)
GLPG : 155.04 (-1.57%)
GILD : 65.86 (+1.00%)
Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP.

GLPG : 155.04 (-1.57%)
Galapagos initiates Phase 1 trial for second Toledo compound

- Second generation compound of novel target class with dual action in inflammatory disorders

GLPG : 155.04 (-1.57%)
Invitation to the special and extraordinary shareholders' meetings

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting.

GLPG : 155.04 (-1.57%)
Invitation to the special and extraordinary shareholders' meetings

Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting.

GLPG : 155.04 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade GLPG with:

Business Summary

Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include...

See More

Key Turning Points

2nd Resistance Point 160.03
1st Resistance Point 157.54
Last Price 155.04
1st Support Level 153.70
2nd Support Level 152.35

See More

52-Week High 191.63
Last Price 155.04
Fibonacci 61.8% 150.90
Fibonacci 50% 138.32
Fibonacci 38.2% 125.73
52-Week Low 85.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar